The CD28 co-stimulatory pathway is well established for T cell activation; however, results from CD28 -/-mice suggest the existence of additional co-stimulatory pathways. Here we report the further characterization of a new member of the CD2 superfamily, NTB-A, important in T cell co-stimulation. NTB-A is expressed on T cells and its expression is upregulated on 
Introduction
T cell activation requires two distinct signals: the first signal through the T cell receptor (TCR) which maintains antigen specificity, and a second co-stimulatory signal, from another receptor such as CD28 (1) . Interaction of CD28 with its ligands B7.1 (CD80) and B7.2 (CD86) expressed on activated antigen presenting cells (APCs) is thought to provide T cells with necessary signals for proper activation and development into effector T cells. Although CD28 is considered a primary receptor for the second signal, CD28 deficient mice can still mount an antigen-specific T cell response, suggesting the existence of other co-stimulatory molecules (2, 3) . For instance, CD8+ cytotoxic T cells are still functional in CD28 deficient mice and these mice also exhibit delayed-type hypersensitivity in response to viral infection. Several other receptors in the CD28 family have been subsequently cloned in recent years. ICOS is a positive regulatory receptor in the family, which can provide co-stimulatory signals to T cells, although ICOS does not activate naïve T cells and is thought to be involved primarily in T helper cell development (4) (5) (6) . The current data in the field indicates that there may be other positive regulatory receptors yet to be identified.
In addition to CD28 family members, other receptors such as those belonging to the CD2 superfamily can also provide the second signal for co-stimulation. Included in the CD2 superfamily are CD2 (LFA-2), CD48, CD58 (LFA-3), CD84, CD150 (SLAM), and CD244 (2B4) (7) (8) (9) (10) (11) (12) (13) (14) . The CD2 family of receptors and ligands are expressed throughout the immune system and play an important role in immune responses. Although CD2 can act as a costimulatory molecule on T cells, CD2 deficient mice exhibit normal T cell responses, suggesting a redundant role for CD2 in T cell co-stimulation (15) . The importance of CD2 becomes much clearer when analyzed in the context of CD28 deficiency. CD2 -/-/CD28 -/-double knockout mice exhibit a much more severe T cell activation defect when compared to CD28 deficient mice, underscoring the important contribution of CD2 in T cell co-stimulation (16) . Still, in the absence of both of these receptors, T cells can be activated under certain circumstances. Clearly, other molecules in addition to CD28 and CD2 are involved in early T cell activation.
Another CD2 superfamily member, CD150, can also provide a co-stimulatory signal to T cells (10) (11) (12) . CD150 is included in a subfamily of receptors that are characterized by extracellular immunoglobulin-like repeats and intracellular binding sites for SAP (SH2D1A), the protein associated with X-linked lymphoproliferative disease (XLP) (9, (17) (18) (19) (20) (21) (22) (23) . The basis for the lymphoproliferation defect seen in XLP patients has been attributed to defects in T cell and NK cell function, although there is no clear understanding of how SAP deficiency contributes to this disease at this time. A better understanding of SAP will come from studying the function of receptors associated with SAP. The most well-studied SAP-associated receptor is CD150. CD150 can provide a co-stimulatory signal to T cells, inducing proliferation and IFN-γ expression. There is also evidence for CD150 involvement in Th1 cell responses, suggesting the importance of this molecule in inflammation and autoimmune disease (10) (11) (12) 24) .
Recently, CD84, another CD2/CD150 family member was found to possess co-stimulatory activity on T cells (25) . Clearly this family of receptors plays an important role in costimulation and lymphocyte regulation, based on its role in lymphocyte activation and association with XLP.
Given the important role of CD2 superfamily members in the immune system, we sought to identify novel members of this family. In our search, we have identified a protein referred to as NTB-A (for T cell COstimulatory Molecule), which shares high amino acid similarity with CD2/CD150 family members. NTB-A is identical to NTB-A and SF2000, cloned by Bottino et al. and Fraser et al., respectively, therefore we refer to our molecule as NTB-A(26) (27) . We show that NTB-A enhances the Th1 cell phenotype and crosslinking of NTB-A induces phosphorylation of NTB-A and SAP association. An NTB-A-Fc fusion protein inhibits Th1 cytokine-induced isotype switching and attenuates EAE, indicating that NTB-A is important for in vivo T cell responses including Th1 cell mediated autoimmune disease. 
Experimental Procedures

Generation of anti-NTB-
Homotypic binding of NTB-A
Human NTB-A-His or 19A-His were coated onto Nunc Maxisorb plates at 2 µg/ml and washed off. After blocking in 10% FCS, NTB-A-Fc or 19A-Fc was titrated on the plate starting at 20 ug/ml. Binding of the Fc fusion proteins were detected using Fc specific goat anti-human IgG (KPL). For detection of cell surface binding, full length human NTB-A or human 19A was transfected into 293T cells. Forty-eight hours after transfection, the cells were washed in PBS, and incubated with 5 µg/ml NTB-A-Fc plus 5% normal goat serum for one hour. Cells were then washed, fixed in 4% paraformaldehyde for 15 minutes. Biotinylated goat anti-human Fc antibody (Jackson Immunoresearch) was added to the cells at 1:400 dilution, and incubated for 30 minutes, followed by washing in PBS. Cy3-conjugated streptavidin (Jackson Immunoresearch) was used at 1:400 dilution for detection. Cell staining was analyzed using a 40X objective and SPOT camera.
NTB-A co-stimulation assay
Costar 96-well U-bottom plates were coated overnight with 0.1 µg/ml anti-CD3 antibody (Pharmingen), 1 µg/ml anti-CD28 (Pharmingen), 1 µg/ml IgG1, or 1 µg/ml anti-NTB-A antibody generated against the extracellular domain of human NTB-A. Human CD4+ T cells were purified from whole blood by negative selection using the CD4 T cell MACs separation kit Co-stimulation of mouse T cells was carried out by coating a plate with 0.1 µg/ml anti-CD3 antibody (Pharmingen), 1 µg/ml anti-CD28 (Pharmingen), 1 µg/ml IgG1, or 1 µg/ml anti-NTB-A that cross-reacted to mouse form. CD4 T cells were isolated from the spleen of a C57/B6 mouse by negative selection using the CD4 T cell isolation kit from Miltyni Biotec. 0.5x10 6 CD4 T cells were activated for 3 days, and on the third day, supernatant was removed for cytokine analysis and the cells were pulsed with [3H]thymidine.
T helper cell differentiation
Naïve human CD4 T cells were isolated from peripheral blood by negative selection and Automacs sorting. Cells were either stimulated with anti-CD3 coated at 2 µg/ml plus anti-CD28 coated at 1 µg/ml (Pharmingen) or with anti-CD3 coated at 2 µg/ml plus anti-NTB-A coated at 1 µg/ml. Immunoprecipitation and Western blot were carried out as described above.
In vivo T dependent B cell responses
C57/B6 mice were immunized I.P. with 100 ug NP(23)-KLH emulsified 1:1 in Complete Freund's Adjuvant. Mice were injected I.P. daily with 100 ug mNTB-A-Fc fusion protein or mIgG1 as a control. After 10 days, serum was obtained and NP-specific immunoglobulins were measured by ELISA. Nunc maxisorb plates were coated overnight with NP(23)-BSA at 10ug/ml. After washing and blocking with 10% FCS, dilutions of serum were then added to the plate for two hours. After washing the serum from the plate, biotinylated anti-isotype specific antibodies were added to the plate. The antibodies used included biotinylated anti-IgM, antiIgG1, anti-IgG2a, and anti-IgG3 (Pharmingen). Detection was carried out with SA-HRP and TMB substrate.
Induction of EAE
Two groups of MBP TCR transgenic mice were immunized with 10 µg Ac1-11/CFA subcutaneously on day 0. One group of 8 mice was injected with 100 µg mNTB-A-Fc I.P. daily and the other group of 9 mice was injected with 100 ug mIgG1 daily. On days 1 and 2, mice were given 200 ng of pertussis toxin I.P. Mice were evaluated daily for signs of disease.
Disease scores were as follows: 0: no disease; 1: tail droop or hind limb weakness; 2: paralysis involving one limb; 3: paralysis involving two limbs; 4: death.
Results
Characterization of NTB-A expression
In a search for novel CD2 family members, we identified a protein referred to as NTB-A (for T cell COstimulatory Molecule). Shortly thereafter, this novel protein was described by Bottino et al. and Fraser et al. as NTB-A and SF2000, respectively (26) (27) . NTB-A has been show to play a role in NK cell activity, however a physiological role in T cells has yet to be examined.
Like other family members NTB-A has two predicted immunoglobulin-like repeats in the extracellular domain as well as three tyrosine motifs in the intracellular domain. Two of these domains bear the TxYxxV/I motif, which is commonly found in the cytoplasmic domains of CD2 family members and act as a SAP-binding domain in CD150. The murine form of NTB-A was also cloned based on sequence homology with the human form and is identical to Ly108 (28) . The amino acid similarity between the mouse and human NTB-A is 46% and the two TxYxxV/I motifs are highly conserved between species. Using both the human and murine form of NTB-A, our studies define a novel role for NTB-A in T cell activation.
Expression of human NTB-A on cell lines was evaluated using a monoclonal antibody raised against the extracellular domain of NTB-A. Our monoclonal antibody detected NTB-A expression on several T cells lines including Jurkat, MOLT3, and MOLT4 (Fig. 1A) . Some, but not all, B cell lines were also positive for NTB-A expression, including Raji, Ramos, and Daudi cell lines. No cell surface expression of NTB-A was detected on other cell lines including a breast adinocarcinoma (MDA231), a monocyte line (THP-1), and a kidney epithelial cell line (293). In addition to cells lines, cell surface expression of NTB-A on human peripheral T cells was also detected (Fig. 1B) . Stimulation of T cells with anti-CD3 and anti-CD28 antibodies led to upregulation of NTB-A surface expression at 24 hours (data not shown), with even higher expression seen at 48 hours post-activation (Fig. 1B) . Human peripheral B cells also express NTB-A, and NTB-A expression increased upon stimulation with anti-CD40 and IL-4 ( Fig.   1C ). High expression of NTB-A on CD4+CD45RO+ memory T cells was also observed (Fig.   1D ). Our data indicate that NTB-A is expressed on both naïve and activated lymphocytes.
Homotypic binding of NTB-A
Homotypic interaction has been demonstrated for CD150 (29, 30) , and it is suggested that other closely related family members (CD84 and Ly9), may also exhibit homotypic binding (25) . To determine whether NTB-A can also act as a self-ligand, we looked for NTB-A:NTB-A association in a number of assays. First, the ability of NTB-A to bind to cell-surface-expressed NTB-A was analysed by transfection of 293T cells with the full length form of human NTB-A or human 19A, a member of the CD150 family of receptors ( Fig. 2A) family members, including CD150, BLAME, or 2B4 (data not shown). In an ELISA assay, we find that NTB-A-Fc can specifically associate with NTB-A-His protein coated on a plate (Fig.   2B ). 19A-Fc does not associate with NTBA-His bound to a plate, and NTBA-Fc does not bind to 19A-His bound to a plate. BIAcore assays were also carried out to determine the affinity of His-tagged NTB-A protein for itself. Homotypic binding of His-NTB-A was found to be a very weak interaction (Kd>100 µM) (data not shown). Interestingly, the CD150-CD150 interaction has been reported to be very weak as well, at 200 µM (29) . Our data indicate that NTB-A can bind to itself very weakly, although because the interaction is to weak, we cannot rule out the existence of other ligands for NTB-A.
Co-stimulation of T cells by NTB-A
To determine whether NTB-A is capable of providing a co-stimulatory signal to T cells, we isolated naïve and memory human peripheral CD4 T cells and stimulated them with anti-NTB-A antibody and a sub-optimal dose of anti-CD3 antibody. Anti-CD3 treatment alone only induced minimal proliferation in the naïve T cells, while higher proliferation was seen in the memory T cells since these cells do not require co-stimulation for activation (Fig. 3A) . (Fig. 3B) . Co-stimulation of murine CD4 T cells was also carried out using antibody that cross-reacts to the murine form of NTB-A (Fig. 3C) . We find similar results as with human T cells, including induced proliferation and IFN-γ expression with NTB-A co-stimulation, indicating the murine and human forms of NTB-A function similarly in T cells. Thus, our results suggest that NTB-A is capable of co-stimulating T cells to a level similar to CD28.
NTB-A promotes Th1 cell phenotype
Given that NTB-A cross-linking can induce proliferation and INF-γ secretion, we next sought to determine whether NTB-A influences Th1 or Th2 cell differentiation. Purified human CD4 T cells were stimulated with anti-CD3 and anti-NTB-A under Th1-inducing conditions or under Th2-inducing conditions. This stimulation was independent of a CD28 signal because no anti-CD28 agonistic reagents were used where anti-NTB-A antibody was used. For comparison, cells were also stimulated with anti-CD3 and anti-CD28 under appropriate Th1 or Th2 conditions. After three days of stimulation, the cells were washed and rested for four days with IL-2. After that time period, all cells were restimulated with anti-CD3 only. Th1 cells stimulated with anti-NTB-A secreted more IFN-γ compared to Th1 cells stimulated with anti-CD28, and Th0 cells also had slightly higher levels of INF-γ (Fig. 4) . Levels of IL-4 and IL-5, Th2-type cytokines, were comparable in all samples, indicating that NTB-A had no effect distinguishable from CD28 on the differentiation of Th2 cells. These results suggest that NTB-A helps to enhance the Th1 cell phenotype by inducing more Th1-type cytokine expression.
Interestingly, effects of NTB-A in enhancing differentiation of T cells to Th1 were completely independent of CD28 signals.
Phosphorylation of NTB-A and SAP association
We have demonstrated that cross-linking of CD3 and NTB-A on T cells leads to proliferation and IFN↑γ expression. We next sought to analyze the molecular events associated with CD3 and NTB-A cross-linking. A hallmark of CD2 family members is the presence of two to four SAPbinding motifs (TxYxxV/I) in the intracellular domain; SAP can bind to the both the phosphorylated and non-phosphorylated forms of CD150, though SAP has a higher affinity for the phosphorylated form (31, 32) . In addition to binding SAP, CD150 has also been reported to bind SHP-2 (22, 24, (33) (34) (35) . Both human and mouse NTB-A have two SAP-binding motifs in the intracellular domain. To determine whether NTB-A also associates with these CD150-associated proteins, Jurkat T cells were treated with pervanadate to induce phosphorylation of NTB-A. NTB-A was immunoprecipitated from cell lysates and the association of SAP, SHP-1, and SHP-2 was determined by western blot. SAP association with NTB-A was not detected in untreated cells. However, SAP did associate with NTB-A in pervanadate treated cells, suggesting a phosphorylation-dependent association of SAP with NTB-A. SHP-1 and SHP-2, although expressed in Jurkat cells, were not found associated with NTB-A in either untreated or in pervanadate-treated cells (Fig. 5A ). This lack of association with SHP-1 or SHP-2 suggests a signaling mechanism distinct from CD150 in T cells. The inhibitory receptor LAIR does associate with SHP-1 an SHP-2 in pervanadate-treated Jurkat cells, ruling out the possibility that SHP-1 and SHP-2 are not capable of being immunoprecipitated in our system (Fig, 5A) .
To study the signaling events following co-stimulation with NTB-A in T cells, we next analyzed the phosphorylation of NTB-A induced by crosslinking CD3 and NTB-A in freshly isolated human T cells ( 
NTB-A-Fc inhibits Th1 cell-induced isotype switching
Our data thus far suggests that NTB-A may act to induce Th1 T cell responses. We next 
NTB-A-Fc delays onset of EAE
The increase in IFN↑γ expression induced by NTB-A suggests that NTB-A may act to skew T cell responses to a Th1 response. To determine the effect of NTB-A in Th1-mediated autoimmune disease, we analyzed the effect of an NTB-A-Fc fusion protein in a murine model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). Myelin Basic Protein (MBP) TCR transgenic mice were immunized with Ac1-11 (NH 2 -terminal peptide from MBP) and treated daily with either NTB-A-Fc or mIgG1 control protein. Disease progression was monitored each day and the onset of disease began at day 5 in the control mice (Fig. 7) . 
